Immunomodulatory Drugs in Acute Myeloid Leukemia Treatment.
作者： Antonio Piccolomo , Claudia Pia Schifone , Vanda Strafella , Giorgina Specchia , Pellegrino Musto
关键词:
摘要: Immunomodulatory drugs (IMiDs) are analogs of thalidomide. They have immunomodulatory, antiangiogenic and proapoptotic properties exert a role in regulating the tumor microenvironment. Recently IMiDs been investigated for their pleiotropic therapeutic applications both solid tumors (melanoma, prostate carcinoma differentiated thyroid cancer) hematological malignancies. Nowadays, they applied de novo relapsed/refractory multiple myeloma, myelodysplastic syndrome, del5q syndrome with specific use lenalidomide B-cell lymphoma. Several studies conducted last few years to explore possible acute myeloid leukemia treatment. Here we report mechanisms action potential future application this disease.
mdpi.com
sci-hub.st 参考文章(63)
Alvaro Aguayo, Elihu Estey, Hagop Kantarjian, Taghi Mansouri, Cristi Gidel, Michael Keating, Francis Giles, Zeev Estrov, Bart Barlogie, Maher Albitar, Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood. ,vol. 94, pp. 3717- 3721 ,(1999) , 10.1182/BLOOD.V94.11.3717
J Munoz, E L Becker, C Lapresle, L J Le Beau, Antigen—Antibody Reactions in Agar II. Elementary Theory and Determination of Diffusion Coefficients of Antigen Journal of Immunology. ,vol. 67, pp. 501- 511 ,(1951)
Maria R. Baer, Ivana Gojo, Novel agents for the treatment of acute myeloid leukemia in the older patient Journal of The National Comprehensive Cancer Network. ,vol. 9, pp. 331- 335 ,(2011) , 10.6004/JNCCN.2011.0029
Anita K. Gandhi, Jian Kang, Courtney G. Havens, Thomas Conklin, Yuhong Ning, Lei Wu, Takumi Ito, Hideki Ando, Michelle F. Waldman, Anjan Thakurta, Anke Klippel, Hiroshi Handa, Thomas O. Daniel, Peter H. Schafer, Rajesh Chopra, Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.). British Journal of Haematology. ,vol. 164, pp. 811- 821 ,(2014) , 10.1111/BJH.12708
Michael Medinger, Klaus Mross, Clinical trials with anti-angiogenic agents in hematological malignancies Journal of Angiogenesis Research. ,vol. 2, pp. 10- 10 ,(2010) , 10.1186/2040-2384-2-10
G Ramsingh, P Westervelt, A F Cashen, G L Uy, K Stockerl-Goldstein, C N Abboud, N Bernabe, R Monahan, J F DiPersio, R Vij, A phase 1 study of concomitant high-dose lenalidomide and 5-azacitidine induction in the treatment of AML. Leukemia. ,vol. 27, pp. 725- 728 ,(2013) , 10.1038/LEU.2012.214
Paul Barr, Pingfu Fu, Hillard Lazarus, Donna Kane, Howard Meyerson, Paul Hartman, Rania Reyes, Richard Creger, Karen Stear, Mary Laughlin, William Tse, Brenda Cooper, Antiangiogenic activity of thalidomide in combination with fludarabine, carboplatin, and topotecan for high-risk acute myelogenous leukemia Leukemia & Lymphoma. ,vol. 48, pp. 1940- 1949 ,(2007) , 10.1080/10428190701573208
K. Sockel, M. Bornhaeuser, E. Mischak-Weissinger, R. Trenschel, M. Wermke, C. Unzicker, G. Kobbe, J. Finke, U. Germing, B. Mohr, J. Greiner, D. Beelen, C. Thiede, G. Ehninger, U. Platzbecker, , Lenalidomide maintenance after allogeneic HSCT seems to trigger acute graft-versus-host disease in patients with high-risk myelodysplastic syndromes or acute myeloid leukemia and del(5q): results of the LENAMAINT trial. Haematologica. ,vol. 97, ,(2012) , 10.3324/HAEMATOL.2012.067629
Hans-Gustaf Ljunggren, Klas Kärre, In search of the ‘missing self’: MHC molecules and NK cell recognition Immunology Today. ,vol. 11, pp. 237- 244 ,(1990) , 10.1016/0167-5699(90)90097-S
Roberto Castelli, Ramona Cassin, Antonino Cannavò, Massimo Cugno, Immunomodulatory Drugs: New Options for the Treatment of Myelodysplastic Syndromes Clinical Lymphoma, Myeloma & Leukemia. ,vol. 13, pp. 1- 7 ,(2013) , 10.1016/J.CLML.2012.09.016